E7386 + lenvatinib

E7386 + lenvatinib is an investigational **combination therapy** of two small-molecule inhibitors under clinical development primarily for advanced, unresectable, or recurrent endometrial cancer, but also being studied in hepatocellular carcinoma (HCC) and colorectal cancer. **E7386** is a potent selective inhibitor targeting the interaction between beta-catenin and CREB binding protein, modulating the Wnt/β-catenin signaling pathway. **Lenvatinib** is a multikinase inhibitor targeting receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including vascular endothelial growth factor receptors (VEGFR 1-3), fibroblast growth factor receptors (FGFR 1-4), platelet-derived growth factor receptor alpha (PDGFRα), RET, and KIT. The combination is designed to enhance anti-angiogenesis and tumor activity relative to monotherapy, with E7386 sensitizing tumors to lenvatinib by impacting pericyte coverage of blood vessels and hypoxia response. Both components are administered orally. Eisai is the primary developer of both drugs and sponsor of the combination’s clinical trials.

Other names

E7386 combination therapyE-7386 combination therapyE 7386 combination therapyE7386 plus lenvatinibE-7386 plus lenvatinibE 7386 plus lenvatinib